Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2015-10-23 21:45:39
Reporting Period:
Filing Date:
Accepted Time:
2015-10-23 21:45:39
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1428522 Radius Health Inc. RDUS Pharmaceutical Preparations (2834) 800145732
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1521111 Gary Hattersley C/o Radius Health, Inc.
950 Winter St.
Waltham MA 02145
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-10-21 1,501 $3.42 1,501 No 4 M Direct
Common Stock Disposition 2015-10-21 1,501 $65.36 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2015-10-21 1,501 $0.00 1,501 $3.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
874 2009-12-31 2016-02-15 No 4 M Direct
  1. The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 10, 2015.
  2. The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $65.00 to $65.97. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.